{
    "clinical_study": {
        "@rank": "26849", 
        "arm_group": [
            {
                "arm_group_label": "Ertugliflozin (5 mg)", 
                "arm_group_type": "Experimental", 
                "description": "Ertugliflozin, 5 mg, oral, once daily for 52 weeks"
            }, 
            {
                "arm_group_label": "Ertugliflozin (15 mg)", 
                "arm_group_type": "Experimental", 
                "description": "Ertugliflozin, 15 mg, oral, once daily for 52 weeks"
            }, 
            {
                "arm_group_label": "Placebo", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Matching placebo to ertuglifozin, oral, once daily for 52 weeks"
            }
        ], 
        "brief_summary": {
            "textblock": "This is a safety and efficacy study of ertugliflozin (MK-8835/PF-04971729) in the treatment\n      of participants with type 2 diabetes mellitus who have inadequate glycemic control on\n      metformin and sitagliptin. The primary objective of the trial is to assess the hemoglobin\n      A1C (A1C)-lowering efficacy of the addition of ertugliflozin compared to the addition of\n      placebo with an underlying hypothesis that addition of treatment with ertugliflozin provides\n      greater reduction in A1C compared with the addition of placebo; the primary objective will\n      be tested for both 5-mg and 15-mg doses of ertugliflozin."
        }, 
        "brief_title": "Safety and Efficacy of Ertugliflozin in the Treatment of Participants With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Metformin and Sitagliptin (MK-8835-006)", 
        "completion_date": {
            "#text": "April 2016", 
            "@type": "Anticipated"
        }, 
        "condition": "Type 2 Diabetes Mellitus", 
        "condition_browse": {
            "mesh_term": [
                "Diabetes Mellitus", 
                "Diabetes Mellitus, Type 2"
            ]
        }, 
        "detailed_description": {
            "textblock": "The duration of the trial will be approximately 69 weeks. This will include a 1-week\n      Screening Period, an up to 12-week wash-off/titration /dose-stabilization period, a 2-week\n      single-blind, placebo run-in period, a 52-week double-blind, placebo-controlled treatment\n      period (including a 26-week Phase A and 26-week Phase B), and a post-treatment telephone\n      contact 14 days after the last dose of blinded investigational product."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Diagnosis of type 2 diabetes mellitus (T2DM)\n\n          -  On stable diabetes therapy of metformin with either sitagliptin or another dipeptidyl\n             peptidase-4 (DPP-4) inhibitor or a sulfonylurea (SU) prior to study participation and\n             is willing to wash-off/switch from another DPP-4 inhibitor/SU to sitagliptin\n\n          -  Body Mass Index (BMI) greater than or equal to 18.0 kg/m^2\n\n          -  Male, postmenopausal female or surgically sterile female\n\n          -  If a female of reproductive potential, agrees to remain abstinent or to use (or have\n             their partner use) 2 acceptable combinations of birth control while participating in\n             the trial and for 14 days after the last use of study drug\n\n        Exclusion Criteria:\n\n          -  History of type 1 diabetes mellitus or a history of ketoacidosis\n\n          -  History of other specific types of diabetes (e.g., genetic syndromes, secondary\n             pancreatic diabetes, diabetes due to endocrine disorders, drug- or chemical-induced,\n             and post-organ transplant)\n\n          -  A known hypersensitivity or intolerance to any sodium-glucose co-transporter 2\n             (SGLT2) or DPP-4 inhibitor\n\n          -  On a weight-loss program or weight-loss medication or other medication associated\n             with weight changes and is not weight stable\n\n          -  Has undergone bariatric surgery within the past 12 months or >12 months and is not\n             weight stable\n\n          -  Has been treated with insulin (except for short-term use [<= 7 days]), injectable\n             antihyperglycemic agents (AHAs) (e.g., pramlintide, exenatide, liraglutide),\n             pioglitazone or rosiglitazone, other sodium-glucose co-transporter 2 (SGLT2)\n             inhibitors, alpha glucosidase inhibitors or meglitinides, bromocriptine (Cycloset\u2122),\n             colesevelam (Welchol\u2122), or any other nonapproved AHAs  within 12 weeks of study\n             participation\n\n          -  Has active, obstructive uropathy or indwelling urinary catheter\n\n          -  History of myocardial infarction, unstable angina, arterial revascularization,\n             stroke, transient ischemic attack, or New York Heart Association (NYHA) functional\n             class III-IV heart failure within 3 months of study participation\n\n          -  A history of malignancy \u22645 years prior to study participation, except for adequately\n             treated basal or squamous cell skin cancer or in situ cervical cancer\n\n          -  Known history of Human Immunodeficiency Virus (HIV)\n\n          -  Has blood dyscrasias or any disorders causing hemolysis or unstable red blood cells\n             or any other clinically significant hematological disorder (such as aplastic anemia,\n             myeloproliferative or myelodysplastic syndromes, thrombocytopenia)\n\n          -  A medical history of active liver disease (other than nonalcoholic hepatic\n             steatosis), including chronic active hepatitis B or C, primary biliary cirrhosis, or\n             active symptomatic gallbladder disease\n\n          -  Has any clinically significant malabsorption condition\n\n          -  If taking thyroid replacement therapy, has not been on a stable dose for at least 6\n             weeks prior to study participation\n\n          -  Has been previously randomized in a study with ertugliflozin\n\n          -  Has participated in other studies involving an investigational drug within 30 days\n             prior or during study participation\n\n          -  Has undergone a surgical procedure within 6 weeks prior to or planned major surgery\n             during study participation\n\n          -  Has a positive urine pregnancy test\n\n          -  Is pregnant or breast-feeding, or is planning to conceive during the trial, including\n             14 days following the last dose of study medication\n\n          -  Planning to undergo hormonal therapy in preparation to donate eggs during the trial,\n             including 14 days following the last dose of study medication\n\n          -  Excessive consumption of alcoholic beverages or binge drinking\n\n          -  Has donated blood or blood products within 6 weeks of study participation or plans to\n             donate blood or blood products at any time during the trial"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "405", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "January 13, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02036515", 
            "org_study_id": "8835-006", 
            "secondary_id": [
                "2013-003697-26", 
                "B1521015"
            ]
        }, 
        "intervention": [
            {
                "arm_group_label": "Ertugliflozin (5 mg)", 
                "description": "Ertugliflozin, oral, 5 mg tablet once daily for 52 weeks", 
                "intervention_name": "Ertugliflozin (5 mg)", 
                "intervention_type": "Drug", 
                "other_name": [
                    "MK-8835", 
                    "PF-04971729"
                ]
            }, 
            {
                "arm_group_label": "Ertugliflozin (15 mg)", 
                "description": "Ertugliflozin, oral, 5 mg and 10 mg tablet once daily for 52 weeks", 
                "intervention_name": "Ertugliflozin (15 mg)", 
                "intervention_type": "Drug", 
                "other_name": [
                    "MK-8835", 
                    "PF-04971729"
                ]
            }, 
            {
                "arm_group_label": [
                    "Ertugliflozin (5 mg)", 
                    "Placebo"
                ], 
                "description": "Matching placebo for ertugliflozin 5 mg, oral, and matching placebo for ertugliflozin 10 mg, oral, once daily for 52 weeks", 
                "intervention_name": "Placebo", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": [
                    "Ertugliflozin (5 mg)", 
                    "Ertugliflozin (15 mg)", 
                    "Placebo"
                ], 
                "description": "Participants are to remain on their stable doses of metformin (oral, >=1500 mg/day) while receiving blinded investigational product during the double-blind treatment period.", 
                "intervention_name": "Metformin", 
                "intervention_type": "Drug", 
                "other_name": [
                    "Glucophage", 
                    "Glucophage XR"
                ]
            }, 
            {
                "arm_group_label": [
                    "Ertugliflozin (5 mg)", 
                    "Ertugliflozin (15 mg)", 
                    "Placebo"
                ], 
                "description": "Participants are to remain on their stable doses of sitagliptin (oral, 100 mg once daily) while receiving blinded investigational product during the double-blind treatment period.", 
                "intervention_name": "Sitagliptin", 
                "intervention_type": "Drug", 
                "other_name": "JANUVIA\u00ae"
            }, 
            {
                "arm_group_label": [
                    "Ertugliflozin (5 mg)", 
                    "Ertugliflozin (15 mg)", 
                    "Placebo"
                ], 
                "description": "Glimepiride rescue medication, oral, once daily, open-label glimepiride; dose determined per the investigator's discretion", 
                "intervention_name": "Glimepiride", 
                "intervention_type": "Drug", 
                "other_name": "AMARYL"
            }, 
            {
                "arm_group_label": [
                    "Ertugliflozin (5 mg)", 
                    "Ertugliflozin (15 mg)", 
                    "Placebo"
                ], 
                "description": "Insulin glargine rescue medication, injectable, as required. In the event that an investigator considers use of glimepiride to not be appropriate for a participant meeting protocol specified glycemic rescue criteria, insulin glargine can be initiated as the rescue medication, and managed by the investigator according to clinical practice guidelines of the local country.", 
                "intervention_name": "Insulin", 
                "intervention_type": "Biological"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Glimepiride", 
                "Sitagliptin", 
                "Insulin", 
                "Metformin"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "lastchanged_date": "May 28, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Azusa", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "91702"
                    }, 
                    "name": "Call for Information (Investigational Site 0050)"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Lincoln", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "95648"
                    }, 
                    "name": "Call for Information (Investigational Site 0030)"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Lawrenceville", 
                        "country": "United States", 
                        "state": "Georgia", 
                        "zip": "30046"
                    }, 
                    "name": "Call for Information (Investigational Site 0063)"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Roswell", 
                        "country": "United States", 
                        "state": "Georgia", 
                        "zip": "30076"
                    }, 
                    "name": "Call for Information (Investigational Site 0072)"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Laurens", 
                        "country": "United States", 
                        "state": "South Carolina", 
                        "zip": "29360"
                    }, 
                    "name": "Call for Information (Investigational Site 0026)"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Austin", 
                        "country": "United States", 
                        "state": "Texas", 
                        "zip": "78745"
                    }, 
                    "name": "Call for Information (Investigational Site 0074)"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Houston", 
                        "country": "United States", 
                        "state": "Texas", 
                        "zip": "77095"
                    }, 
                    "name": "Call for Information (Investigational Site 0085)"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Tomball", 
                        "country": "United States", 
                        "state": "Texas", 
                        "zip": "77375"
                    }, 
                    "name": "Call for Information (Investigational Site 0084)"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Midvale", 
                        "country": "United States", 
                        "state": "Utah", 
                        "zip": "84047"
                    }, 
                    "name": "Call for Information (Investigational Site 0038)"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Salt Lake City", 
                        "country": "United States", 
                        "state": "Utah", 
                        "zip": "84124"
                    }, 
                    "name": "Call for Information (Investigational Site 0037)"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Salt Lake City", 
                        "country": "United States", 
                        "state": "Utah", 
                        "zip": "84107"
                    }, 
                    "name": "Call for Information (Investigational Site 0073)"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "South Chesterfield", 
                        "country": "United States", 
                        "state": "Virginia", 
                        "zip": "23803"
                    }, 
                    "name": "Call for Information (Investigational Site 0035)"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "3", 
        "official_title": "A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Clinical Trial to Evaluate the Safety and Efficacy of Ertugliflozin (MK-8835/PF-04971729) in the Treatment of Subjects With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Metformin and Sitagliptin", 
        "overall_contact": {
            "last_name": "Toll Free Toll Free Number", 
            "phone": "1-888-577-8839"
        }, 
        "overall_official": {
            "affiliation": "Merck Sharp & Dohme Corp.", 
            "last_name": "Medical Director", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "October 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "measure": "Change from baseline in hemoglobin A1C at Week 26", 
                "safety_issue": "No", 
                "time_frame": "Baseline and Week 26"
            }, 
            {
                "measure": "Number of Participants Experiencing An Adverse Event (AE)", 
                "safety_issue": "Yes", 
                "time_frame": "Up to Week 54"
            }, 
            {
                "measure": "Number of Participants Discontinuing Study Treatment Due to an AE", 
                "safety_issue": "Yes", 
                "time_frame": "Up to Week 52"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02036515"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Change from baseline in fasting plasma glucose (FPG) at Week 26", 
                "safety_issue": "No", 
                "time_frame": "Baseline and Week 26"
            }, 
            {
                "measure": "Change from baseline in body weight at Week 26", 
                "safety_issue": "No", 
                "time_frame": "Baseline and Week 26"
            }, 
            {
                "measure": "Number of participants with an A1C <7% (53 mmol/mol) at Week 26", 
                "safety_issue": "No", 
                "time_frame": "Week 26"
            }, 
            {
                "measure": "Change from baseline in systolic blood pressure at Week 26", 
                "safety_issue": "No", 
                "time_frame": "Baseline and Week 26"
            }
        ], 
        "source": "Merck Sharp & Dohme Corp.", 
        "sponsors": {
            "collaborator": {
                "agency": "Pfizer", 
                "agency_class": "Industry"
            }, 
            "lead_sponsor": {
                "agency": "Merck Sharp & Dohme Corp.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "March 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}